Why is Regeneron Pharmaceuticals, Inc. stock rising?
EYLEA HD prefilled-syringe approval and launch targeted before end-2026
Cemdisiran U.S. launch in generalized myasthenia gravis, with FDA decision expected in November 2026
Garetosmab potential first-to-market approval for FOP expected in August 2026
Olatorepatide obesity Phase III program and Praluent combination advancing over the next few months
Remaining Factor XI Phase III anticoagulation studies to be initiated in 2026
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Regeneron Pharmaceuticals, Inc. and 4,900+ companies.